What is it about?
The study provides evidence that YC-1 suppresses the viability of cisplatin-resistant CAR cells by inhibiting cell proliferation, arresting cell cycle at G0/G1 phase and triggering mitochondria-mediated apoptosis. The induction by YC-1 is concentration-dependent and time-dependent in decreasing the viability of CAR cells, and the progress could be analysed by real-time image analysis of CAR cells.
Featured Image
Why is it important?
Oral cancer is a serious and fatal disease. Cisplatin is the first line of chemotherapeutic agent for oral cancer therapy. However, the development of drug resistance and severe side effects cause tremendous problems. To meet current need, designing novel compounds as well as discovering new targeting molecules that can overcome the resistance to chemotherapeutic drugs in oral cancer are clinically important.
Perspectives
Discovering and exploring novel therapeutic strategy and underlying molecular mechanisms has been a major research focus in oral cancer therapy. Studies on various cancer cells demonstrated that YC-1 possessed significant anti-cancer activities through several pathways.
Dr Jai-Sing Yang
China Medical University
Read the Original
This page is a summary of: YC-1 induces G0/G1 phase arrest and mitochondria-dependent apoptosis in cisplatin-resistant human oral cancer CAR cells, BioMedicine, June 2017, EDP Sciences,
DOI: 10.1051/bmdcn/2017070205.
You can read the full text:
Contributors
The following have contributed to this page
